Lincoln, NE – January 29, 2020 – Adjuvance Technologies announced today that it has received a $20 million Series A investment from Morningside Venture Investments Limited. The funds from the investment will be deployed to advance their first product through a proof-of-concept clinical trial.
“We are pleased to receive this investment from Morningside”, said Tyler Martin, MD, Chairman and CEO of Adjuvance. “They are a top tier life science venture investor, providing important validation of our technology. More importantly, together we have strategic alignment for building our business, and getting innovative vaccines to the people who need them.”
Lisa Sypal, Adjuvance Technologies’ Director of Investor Relations, said the company is also appreciative of the local support they’ve received as well. “Our partnership with Nebraska Innovation Campus and the early support provided by groups like the Nebraska Department of Economic Development, Invest Nebraska and local angel investors have been a key component in our ability to advance our mission.”
About Adjuvance Technologies: Adjuvance Technologies, Inc. is a privately held biopharmaceutical company focused on empowering health through fundamental breakthroughs in vaccine adjuvant design and manufacturing. Its lead adjuvant, TQL-1055, is in pre-clinical development for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy. More information is available at www.adjuvancetech.wpengine.com.
About Morningside Venture Investments: Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. It is engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. Morningside is an active investor in early-stage life science companies formed around new technologies that represent a high degree of novelty over existing technologies. More information is available at www.morningside.com.
For more information, please contact: